Enhancing extinction learning in posttraumatic stress disorder with brief daily imaginal exposure and methylene blue: A randomized controlled trial

Journal of Clinical Psychiatry

Volumn 78, Issue 7, 2017, Pages e782-e789

  Zoellner, Lori A ^a   Telch, Michael ^b   Foa, Edna B ^c   Farach, Frank J ^a   McLean, Carmen P ^c   Gallop, Robert ^d   Bluett, Ellen J ^e   Cobb, Adam ^b   Gonzalez Lima, F ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d WEST CHESTER UNIVERSITY   (United States)

^e UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLENE BLUE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; EXPOSURE THERAPY; FEMALE; FOLLOW UP; HUMAN; IMAGINAL EXPOSURE; INJURY; MALE; MENTAL DISEASE; MENTAL DISEASE ASSESSMENT; MENTAL FUNCTION; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WORKING MEMORY; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG EFFECTS; IMPLOSIVE THERAPY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATIENT DROPOUT; PROCEDURES; PSYCHOLOGICAL INTERVIEW; PSYCHOLOGY; SHORT TERM PSYCHOTHERAPY; STRESS DISORDERS, POST-TRAUMATIC;

ADULT; CHRONIC DISEASE; COMBINED MODALITY THERAPY; EXTINCTION, PSYCHOLOGICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMPLOSIVE THERAPY; INTERVIEW, PSYCHOLOGICAL; MALE; METHYLENE BLUE; MIDDLE AGED; PATIENT DROPOUTS; PSYCHOTHERAPY, BRIEF; QUALITY OF LIFE; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 85028330983     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.16m10936     Document Type: Article

References (50)

1. Watts BV, Schnurr PP, Mayo L, et al. Metaanalysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013;74(6):e541-e550.
2. Eftekhari A, Ruzek JI, Crowley JJ, et al. Effectiveness of national implementation of prolonged exposure therapy in Veterans Affairs care. JAMA Psychiatry. 2013;70(9):949-955.
3. Powers MB, Halpern JM, Ferenschak MP, et al. A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev. 2010;30(6):635-641.
4. Huang S, Du F, Shih YY, et al. Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia. Neuroimage. 2013;72:237-242.
5. Callaway NL, Riha PD, Bruchey AK, et al. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav. 2004;77(1):175-181.
6. Meissner PE, Mandi G, Witte S, et al. Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malar J. 2005;4:45.
7. Naylor GJ, Martin B, Hopwood SE, et al. A twoyear double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry. 1986;21(10):915-920.
8. Naylor GJ, Smith AH, Connelly P. A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry. 1987;22(5):657-659.
9. Naylor GJ, Smith AH, Connelly P. Methylene blue in mania. Biol Psychiatry. 1988;24(8):941-942.
10. Peter C, Hongwan D, Küpfer A, et al. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000;56(3):247-250.
11. Quirk GJ, Garcia R, González-Lima F. Prefrontal mechanisms in extinction of conditioned fear. Biol Psychiatry. 2006;60(4):337-343.
12. Callaway NL, Riha PD, Wrubel KM, et al. Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats. Neurosci Lett. 2002;332(2):83-86.
13. Riha PD, Bruchey AK, Echevarria DJ, et al. Memory facilitation by methylene blue: dosedependent effect on behavior and brain oxygen consumption. Eur J Pharmacol. 2005;511(2-3):151-158.
14. Gonzalez-Lima F, Bruchey AK. Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem. 2004;11(5):633-640.
15. Wrubel KM, Riha PD, Maldonado MA, et al. The brain metabolic enhancer methylene blue improves discrimination learning in rats. Pharmacol Biochem Behav. 2007;86(4):712-717.
16. Telch MJ, Bruchey AK, Rosenfield D, et al. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry. 2014;171(10):1091-1098.
17. Bontempo A, Panza KE, Bloch MH. D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. J Clin Psychiatry. 2012;73(4):533-537.
18. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118-1126.
19. Rodrigues H, Figueira I, Lopes A, et al. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? a meta-analysis. PLoS One. 2014;9(7):e93519.
20. Barrett D, Shumake J, Jones D, et al. Metabolic mapping of mouse brain activity after extinction of a conditioned emotional response. J Neurosci. 2003;23(13):5740-5749.
21. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96(1):32-45.
22. Nacasch N, Huppert JD, Su Y-J, et al. Are 60-minute prolonged exposure sessions with 20-minute imaginal exposure to traumatic memories sufficient to successfully treat PTSD? a randomized noninferiority clinical trial. Behav Ther. 2015;46(3):328-341.
23. Mueser KT, Rosenberg SD, Xie H, et al. A randomized controlled trial of cognitivebehavioral treatment for posttraumatic stress disorder in severe mental illness. J Consult Clin Psychol. 2008;76(2):259-271.
24. Zoellner LA, Feeny NC, Eftekhari A, et al. Changes in negative beliefs following three brief programs for facilitating recovery after assault. Depress Anxiety. 2011;28(7):532-540.
25. Foa EB, Riggs DS, Dancu CV, et al. Reliability and validity of a brief instrument for assessing posttraumatic stress disorder. J Trauma Stress. 1993;6(4):459-473.
26. Foa EB, Tolin DF. Comparison of the PTSD Symptom Scale-Interview Version and the Clinician-Administered PTSD Scale. J Trauma Stress. 2000;13(2):181-191.
27. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised Edition. Washington, DC: US Department of Health, Education, and Welfare; 1976.
28. Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624-629.
29. Skre I, Onstad S, Torgersen S, et al. High interrater reliability for the Structured Clinical Interview for DSM-III-R Axis I (SCID-I). Acta Psychiatr Scand. 1991;84(2):167-173.
30. Williams JB, Gibbon M, First MB, et al. The Structured Clinical Interview for DSM-III-R (SCID), II: multisite test-retest reliability. Arch Gen Psychiatry. 1992;49(8):630-636.
31. Foa EB, Cashman L, Jaycox LH, et al. The validation of a self-report measure of PTSD: the PTSD Diagnostic Scale. Psychol Assess. 1997;9:445-451.
32. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583.
33. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDSSR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73-82.
34. Rush AJ, Trivedi MH, Carmody TJ, et al. Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology. 2005;30(2):405-416.
35. Foa EB, Ehlers A, Clark DM, et al. The Posttraumatic Cognitions Inventory (PTCI): development and validation. Psychol Assess. 1999;11(3):303-314.
36. Unsworth N, Heitz RP, Schrock JC, et al. An automated version of the operation span task. Behav Res Methods. 2005;37(3):498-505.
37. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30(6):473-483.
38. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36), II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247-263.
39. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95.
40. Leon AC, Shear MK, Portera L, et al. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol. 1992;27(2):78-82.
41. Wolpe J. The Practice of Behavior Therapy. 4th ed. Elmsford, NY: Pergamon Press; 1990.
42. Marshall RD, Lewis-Fernandez R, Blanco C, et al. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety. 2007;24(2):77-84.
43. Foa EB, Hembree EA, Rothbaum BO. Prolonged Exposure for PTSD: Emotional Processing of Traumatic Experiences. New York, NY: Oxford University Press; 2007.
44. Doctor JN. Recovery after treatment and sensitivity to base rate. J Consult Clin Psychol. 1999;67(2):219-227.
45. Robjant K, Fazel M. The emerging evidence for Narrative Exposure Therapy: a review. Clin Psychol Rev. 2010;30(8):1030-1039.
46. van Minnen A, Foa EB. The effect of imaginal exposure length on outcome of treatment for PTSD. J Trauma Stress. 2006;19(4):427-438.
47. Smits JAJ, Hofmann SG, Rosenfield D, et al. D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J Consult Clin Psychol. 2013;81(6):1100-1112.
48. Milad MR, Quirk GJ. Fear extinction as a model for translational neuroscience: ten years of progress. Annu Rev Psychol. 2012;63:129-151.
49. Rodriguez P, Zhou W, Barrett DW, et al. Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain. Radiology. 2016;281(2):516-526.
50. de Kleine RA, Smits JAJ, Hendriks G-J, et al. Extinction learning as a moderator of D-cycloserine efficacy for enhancing exposure therapy in posttraumatic stress disorder. J Anxiety Disord. 2015;34:63-67.